We received our last update on 3D bioprinting company Organovo a couple of weeks ago, when it released a plethora of new information regarding the performance of its 3D printed kidney and liver tissue in research and testing. The news was all good - the data so far shows that the 3D printed tissue has great potential for pharmaceutical testing, and the possibility of creating functional 3D printed organs still hovers as a goal somewhere in the future. This week, Organovo is presenting its research in person at the Society of Toxicology's (SOT) 56th Annual Meeting and ToxExpo, which is taking place in Baltimore from March 12 to 16. While the program is already well underway, Organovo is by no means done yet; the company is staying busy at the conference with a total of eight presentations about its ExVive 3D Bioprinted Human Liver and Kidney Tissues and their effectiveness in assessing drug safety and detecting liver injury and kidney toxicity. Read more at 3DPrint.com: http://3dprint.com/167833/organovo-society-of-toxicology/ ‎